Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
Want to see ENLV full AI Analyst Report?
ENLV Stock Chart & Stats
$0.86
-$0.07(-5.60%)
At close: 4:00 PM EST
$0.86
-$0.07(-5.60%)
Day’s Range― - ―
52-Week Range$0.66 - $2.10
Previous CloseN/A
Volume59.48K
Average Volume (3M)182.02K
Market Cap
$204.87M
Enterprise Value$18.33M
Total Cash (Recent Filing)$5.87M
Total Debt (Recent Filing)$641.00K
Price to Earnings (P/E)<0.1
Beta0.56
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)27.02
Shares Outstanding241,048,720
10 Day Avg. Volume216,695
30 Day Avg. Volume182,016
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-55.20
Enterprise Value/Ebitda-1.28
Forecast
1Y Price Target
$20.00Price Target Upside2225.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt and near-zero debt-to-equity materially reduce financial distress risk and give management flexibility to fund R&D or restructure financing. Over 2–6 months this durable balance-sheet conservatism supports runway and bargaining power with lenders and partners.
FDA IND Clearance For Phase 2bRegulatory clearance to run a statistically powered global Phase 2b is a durable operational milestone: it advances the lead asset toward registrational pathways, enables larger datasets in a large unmet market, and meaningfully raises the long‑term commercial and partnership optionality.
Large Treasury Assets Provide Capital OptionalityMaterial digital‑asset and derivative holdings have meaningfully strengthened reported equity and provide non‑operating capital optionality to fund trials, collateralize financing, or pursue buybacks. This structural capital buffer can extend runway and reduce immediate dilution needs.
Bears Say
No Operating Revenue, Sustained LossesAs a clinical‑stage company with effectively zero recurring revenue, the firm relies on financing and non‑operating gains. Persistent operating losses mean the business lacks durable internal cash generation, lengthening the path to self‑sustaining operations and increasing financing dependency.
Consistent Operating Cash BurnNegative operating and free cash flows across multiple years indicate ongoing burn that necessitates repeat external funding. This structural cash deficit increases dilution risk or reliance on asset monetization, constraining strategic choices and pace of clinical development.
Balance‑sheet Volatility From Concentrated Crypto ExposureConcentrated holdings and large unrealized gains introduce material balance‑sheet volatility and reliance on token market dynamics. Regulatory, market, or protocol adverse moves could rapidly erode equity and collateral value, weakening the company’s durable funding base and strategic optionality.
Enlivex News
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $0.66 and its highest was $2.10 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is $204.87M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Apr 23, 2027 which is in 323 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 22, 2026. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 241,048,720 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went down -0.417%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in ENLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enlivex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (2225.58% Upside)
$20.00 (2225.58% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.96%
12-Months-Change
Fundamentals
Return on Equity
248.08%
Trailing 12-Months
Asset Growth
8304.66%
Trailing 12-Months
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
ENLV Earnings Call
Q4 2026
0:00 / 0:00
ENLV Stock 12 Month Forecast
Average Price Target
$20.00
▲(2225.58% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.01% Mutual Funds
0.98% Other Institutional Investors
97.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---